

Changhoon Yoo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3090427/changhoon-yoo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

157
papers

2,180
citations

24
h-index

40
g-index

176
ext. papers

2,935
ext. citations

4.5
avg, IF

4.81
L-index

#	Paper	IF	Citations
157	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8 T Cells and Features of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018 , 155, 1936-1950.e17	13.3	141
156	Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2013 , 14, 1175-82	21.7	134
155	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. <i>European Journal of Cancer</i> , 2015 , 51, 482-488	7.5	84
154	The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 980-5	2.8	81
153	Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1554-9	2.2	76
152	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. <i>Investigational New Drugs</i> , 2018 , 36, 732-741	4.3	69
151	Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. <i>American Journal of Hematology</i> , 2007 , 82, 821-3	7.1	69
150	Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Annals of Hematology</i> , 2011 , 90, 797-802	3	66
149	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with pretreated biliary tract cancer 2020 , 8,		49
148	Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 209-215	3.5	43
147	Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. <i>European Journal of Cancer</i> , 2019 , 120, 31-39	7.5	38
146	Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 391-7	3	38
145	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. <i>British Journal of Cancer</i> , 2017 , 116, 561-567	8.7	35
144	Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. <i>Blood Research</i> , 2014 , 49, 148-53	1.4	33
143	Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. <i>Annals of Thoracic Surgery</i> , 2012 , 94, 1862-8	2.7	32
142	BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. <i>Leukemia Research</i> , 2011 , 35, 183-7	2.7	32
141	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. <i>Investigational New Drugs</i> , 2013 , 31, 1602-8	4.3	31

140	Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. <i>Journal of Breast Cancer</i> , 2012 , 15, 203-10	3	30
139	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. <i>Cancer Research and Treatment</i> , 2020 , 52, 594-603	5.2	30
138	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019 , 37, 567-572	4.3	30
137	Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. <i>Oncotarget</i> , 2017 , 8, 46337-46347	3.3	29
136	Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 565-75	3.5	26
135	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019 , 51, 510-518	5.2	25
134	CD226CD8 T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. <i>Cancer Immunology Research</i> , 2020 , 8, 912-925	12.5	25
133	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 226-33	7.6	24
132	Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. <i>Cancer Research and Treatment</i> , 2016 , 48, 546-52	5.2	24
131	Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. <i>Cancer Research and Treatment</i> , 2017 , 49, 759-765	5.2	24
130	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 139-146	3.5	23
129	Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. <i>British Journal of Cancer</i> , 2016 , 114, 1185-90	8.7	23
128	Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1435-43	3.5	23
127	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016 , 7, 76934-76943	3.3	22
126	Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. <i>Investigational New Drugs</i> , 2014 , 32, 271-8	4.3	21
125	Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. <i>Annals of Hematology</i> , 2014 , 93, 995-1000	3	20
124	Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 139-49	3.5	19
123	Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. <i>Investigational New Drugs</i> , 2013 , 31, 1367-74	4.3	19

122	Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 473-80	3.5	19
121	Stereotactic body radiation therapy for locally advanced pancreatic cancer. <i>PLoS ONE</i> , 2019 , 14, e0214970	3.7	18
120	Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection. <i>Clinical Lung Cancer</i> , 2015 , 16, e203-12	4.9	18
119	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. <i>Hematological Oncology</i> , 2016 , 34, 22-7	1.3	18
118	Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. <i>Sarcoma</i> , 2009 , 2009, 360875	3.1	18
117	Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017 , 8, 38592-38601	3.3	18
116	Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncology</i> , 2021 , 22, 1560-1572	21.7	18
115	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. <i>Cancers</i> , 2019 , 11,	6.6	17
114	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020 , 40, 2544-2552	7.9	17
113	Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. <i>Blood Research</i> , 2014 , 49, 253-8	1.4	17
112	Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2018 , 50, 1324-1330	5.2	17
111	Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 285-91	3.5	16
110	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020 , 9, 613-624	9.1	16
109	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919871126	5.4	15
108	Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. <i>British Journal of Cancer</i> , 2020 , 123, 362-368	8.7	15
107	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. <i>Liver International</i> , 2020 , 40, 2263-2271	7.9	15
106	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021 , 10, 107-114	9.1	15
105	Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. <i>Investigational New Drugs</i> , 2012 , 30, 1703-8	4.3	14

104	Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020 , 12,	6.6	14
103	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021 , 41, 1389-1397	7.9	14
102	Prognostic impact of Eμmicroglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 688-93	1.9	13
101	Verrucous carcinoma of the esophagus. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 803-6	5.2	13
100	Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2940-7	3.1	11
99	Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. <i>Cancer Research and Treatment</i> , 2018 , 50, 1175-1185	5.2	11
98	Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2020 , 52, 254-262	5.2	11
97	Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4006-4006	2.2	11
96	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. <i>Blood Research</i> , 2017 , 52, 285-292	1.4	10
95	Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma. <i>Korean Journal of Internal Medicine</i> , 2010 , 25, 301-8	2.5	10
94	Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score. <i>Radiology</i> , 2020 , 296, 541-551	20.5	10
93	Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. <i>Investigational New Drugs</i> , 2019 , 37, 584-590	4.3	10
92	Companion diagnostics for the targeted therapy of gastric cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10948-55	5.6	9
91	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920953294	5.4	9
90	CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. <i>European Radiology</i> , 2021 , 31, 813-823	8	9
89	Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. <i>Journal of Digestive Diseases</i> , 2017 , 18, 480-486	3.3	8
88	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. <i>Liver International</i> , 2021 , 41, 1398-1408	7.9	8
87	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). <i>ESMO Open</i> , 2021 , 6, 100049	6	8

86	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920923424	5.4	7
85	Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients. <i>Journal of Korean Medical Science</i> , 2013 , 28, 1248-52	4.7	7
84	Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index. <i>ESMO Open</i> , 2021 , 6, 100119	6	7
83	Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. <i>Investigational New Drugs</i> , 2018 , 36, 163-169	4.3	7
82	Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. <i>Cancers</i> , 2021 , 13,	6.6	7
81	Tumour-to-liver ratio determined by [Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. <i>EJNMMI Research</i> , 2020 , 10, 63	3.6	6
80	Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. <i>Investigational New Drugs</i> , 2018 , 36, 496-502	4.3	6
79	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 182-189	7.6	5
78	EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
77	Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). <i>European Journal of Cancer</i> , 2016 , 52, 201-8	7.5	5
76	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. <i>Investigational New Drugs</i> , 2014 , 32, 753-61	4.3	5
75	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2021 ,	7.9	5
74	Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. <i>Anticancer Research</i> , 2019 , 39, 1005-1012	2.3	5
73	A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 406-15	5.2	5
72	Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. <i>Cancer Research and Treatment</i> , 2019 , 51, 901-909	5.2	5
71	Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. <i>Cancers</i> , 2021 , 13,	6.6	5
70	Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021 , 41, 2189-2199	7.9	5
69	Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	5

68	Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. <i>Oncologist</i> , 2019 , 24, e1212-e1218	5.7	5
67	Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. <i>Investigational New Drugs</i> , 2019 , 37, 763-770	4.3	5
66	Rivaroxaban Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. <i>In Vivo</i> , 2020 , 34, 829-837	2.3	4
65	Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. <i>Journal of Breast Cancer</i> , 2011 , 14, 135-9	3	4
64	Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA10502-LBA10502	2.2	4
63	Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017 , 8, 76712-76721	3.3	4
62	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3665-3671	4.9	4
61	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	4
60	Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. <i>British Journal of Surgery</i> , 2021 ,	5.3	4
59	Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2021 , 53, 162-171	5.2	4
58	Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. <i>Cancer Medicine</i> , 2019 , 8, 1034-1043	4.8	3
57	Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. <i>Annals of Surgical Oncology</i> , 2015 , 22 Suppl 3, S362-9	3.1	3
56	Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging. <i>Acta Radiologica</i> , 2021 , 62, 1548-1558	2	3
55	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. <i>Cancers</i> , 2021 , 13,	6.6	3
54	Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211003053	5.4	3
53	Implication of CD69 CD103 tissue-resident-like CD8 T cells as a potential immunotherapeutic target for cholangiocarcinoma. <i>Liver International</i> , 2021 , 41, 764-776	7.9	3
52	LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.. <i>Molecular Therapy</i> , 2022 ,	11.7	3
51	Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019 , 121, 819-826	8.7	2

50	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4078-4078	2.2	2
49	Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020 , 27, 604-613	2.8	2
48	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. <i>Cancer Research and Treatment</i> , 2021 , 53, 291-300	5.2	2
47	Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysis. <i>Clinical Nuclear Medicine</i> , 2021 , 46, 723-731	1.7	2
46	Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells.. <i>Anticancer Research</i> , 2022 , 42, 471-482	2.3	2
45	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 175883592210979	5.4	2
44	Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
43	Prognostic Impact of Mid-Treatment PET in Patients with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment PET. <i>Blood</i> , 2009 , 114, 3949-3949	2.2	1
42	Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 354-354	3.2	1
41	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG). <i>Journal of Clinical Oncology</i> , 2019 , 37, 344-344	2.2	1
40	A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16643-e16643	2.2	1
39	Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10550-10550	2.2	1
38	Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA10502-LBA10502	2.2	1
37	Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021 , 16, 401-410	5	1
36	Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. <i>Cancer Research and Treatment</i> , 2021 , 53, 424-435	5.2	1
35	Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. <i>European Radiology</i> , 2021 , 31, 864-874	8	1
34	Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 658564	5.3	1
33	Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2013 , 97, 232-9	2.3	0

32	Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 415-415	2.2	○
31	Real-world data analysis of patients with cancer of unknown primary. <i>Scientific Reports</i> , 2021 , 11, 23074	4.9	○
30	Radiation therapy for recurrent extrahepatic bile duct cancer. <i>PLoS ONE</i> , 2021 , 16, e0253285	3.7	○
29	Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 272-272	2.2	○
28	Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. <i>International Journal of Biological Markers</i> , 2018 , 33, 432-438	2.8	
27	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.. <i>Lancet Oncology</i> , 2022 , 23, e12	21.7	
26	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS621-TPS621	2.2	
25	Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 546-546	2.2	
24	Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 410-410	2.2	
23	Adjuvant gemcitabine (GEM) versus gemcitabine plus capecitabine (GEMCAP) in resected pancreatic adenocarcinoma: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 547-547	2.2	
22	Efficacy and safety of mFOLFIRINOX in patients with borderline resectable and locally advanced unresectable pancreatic cancer: Intention-to-treat population analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 720-720	2.2	
21	Clinical benefit of maintenance therapy for patients with advanced biliary tract cancer without progression on first-line gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 357-357	2.2	
20	Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11537-11537	2.2	
19	DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4078-4078	2.2	
18	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4624-4624	2.2	
17	Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer (GC): Clinical implications for prognosis and peritoneal recurrence.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 23-23	2.2	
16	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4026-4026	2.2	
15	Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4057-4057	2.2	

- 14 Efficacy of chemotherapy in patients with pancreatic acinar cell carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 308-308 2.2
- 13 Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. *Cancer Research and Treatment*, **2016**, 48, 499-507 5.2
- 12 Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients.. *Journal of Clinical Oncology*, **2017**, 35, 425-425 2.2
- 11 Timing of G-CSF Injection for Effective Autologous Stem Cell Collection. *Blood*, **2008**, 112, 4439-4439 2.2
- 10 Comparison Between CD20-Negative and CD20-Positive Diffuse Large B Cell Lymphoma; Characteristics and Clinical Outcome. *Blood*, **2010**, 116, 4891-4891 2.2
- 9 Short Course Adjuvant Chemotherapy for Localized Diffuse Large B-Cell Lymphoma After Complete Resection.. *Blood*, **2010**, 116, 2824-2824 2.2
- 8 Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. *Journal of Clinical Oncology*, **2012**, 30, e11508-e11508 2.2
- 7 Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, e31-4 7.1
- 6 Prognostic Impact Of Beta-2 Microglobulin In Patients With Non-Gastric Marginal Zone Lymphoma. *Blood*, **2013**, 122, 4297-4297 2.2
- 5 A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. *Journal of Gastrointestinal Cancer*, **2021**, 1 1.6
- 4 Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study.. *Journal of Clinical Oncology*, **2021**, 39, 339-339²
- 3 -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. *Journal of Breast Cancer*, **2018**, 21, 45-50 3
- 2 Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. *Targeted Oncology*, **2021**, 16, 653-661 5
- 1 Real-world outcomes of adjuvant gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359221097490 5.4